Medical Management of Diabetes and Heart Disease - part 1 pps
Medical Management of Diabetes and Heart Disease - part 1 pps
... York, NY 10 016
tel: 21 2-6 9 6-9 000; fax: 21 2-6 8 5-4 540
Eastern Hemisphere Distribution
Marcel Dekker AG
Hutgasse 4, Postfach 812 , CH-40 01 Basel, Switzerland
tel: 4 1- 6 1- 2 6 1- 8 482; fax: 4 1- 6 1- 2 6 1- 8 896
World ... Hodis, and Wendy J. Mack
12 . Management of Patients with Diabetes and Coronary Artery
Disease 18 5
William E. Boden
13 . Pathoph...
Medical Management of Diabetes and Heart Disease - part 2 pps
... ischemic heart disease. JAMA 19 98; 279 :19 55 19 61.
52. Kannel WB. Lipids, diabetes, and coronary heart disease: Insights from the Framing-
ham Study. Am Heart J 19 85; 11 0 :11 00 11 07.
53. Kannel ... Circula-
tion 19 99; 10 0 :12 3 12 8.
50. Despre
´
s J-P. The insulin resistance-dyslipidemia syndrome: The most prevalent
cause of coronary artery disease? Can Med Assoc...
Medical Management of Diabetes and Heart Disease - part 7 pps
... high-risk patients with diabetes. The MICRO-HOPE study. Diabetes Care 19 96;
19 :12 25 12 28.
30. Godsland JK, Stevenson JC. Insulin resistance: syndrome or tendency? Lancet
19 95; 346 :10 0 10 3.
31. ... 2
diabetes: a 15 -year follow-up from the time of diagnosis. Diabetes Care 19 98; 21:
18 61 18 69.
64. Nitenberg A, Paycha F, Ledoux S, Sachs R, Attali JR, Valensi P. Coronary...
Medical Management of Diabetes and Heart Disease - part 3 ppt
... with type
2 diabetes. Proc Assoc Am Physicians 19 99; 11 1: 313 – 318 .
58 Cefalu
of coronary heart disease: results from two population studies in Finland. Diabetes
Care 19 79; 2 :13 1 14 1.
21. White MF, ... Care 19 98; 21: 113 8–
11 45.
7. Harris MI. Diabetes in America: Epidemiology and scope of the problem. Diabetes
Care 19 98; 21: C 11 C14.
8. Kannel WB, Hjortland...
Medical Management of Diabetes and Heart Disease - part 4 docx
... 10
6
30–80 55–80 5 15 10 –20
IDL 1. 006 1. 019 5 10 ϫ 10
6
25–35 20–50 20–40 15 –25
LDL 1. 019 1. 063 2.3 ϫ 10
6
18 –25 5 15 40–50 20–25
HDL 1. 063 1. 21 1.7–3.6 ϫ 10
6
5 12 5 10 15 –25 20–30
Density: g/dL; MW: ... Intern
Med 19 97; 15 7:2 413 –2446.
86. 19 99 World Health Organization-International Society of Hypertension guidelines
for the management of hypertension...
Medical Management of Diabetes and Heart Disease - part 5 pot
... (IRS -1 and IRS-2), and activation of the phosphoinositol 3′ kinase
(PI-3′-K) pathway. On the other hand, cell growth and differentiation are regu-
lated primarily by the SHC, GRB-2, and the MAP-kinase ... system. N Engl J
Med 19 96; 334:374–3 81.
9. Chen YD-I, Reaven GM. Insulin resistance and atherosclerosis. Diabetes Rev 19 97;
5:3 31 342.
Syndrome X 11 9
Each of the b...
Medical Management of Diabetes and Heart Disease - part 6 pdf
... Endocrinol Metab 20 01; 86 :11 75 11 80.
Diagnosis of Heart Disease in Diabetic and Prediabetic Subjects 16 5
lar risk factors like hypertension, dyslipidemia, family history of CAD, and smok-
ing, as well ... patterns of insulin secretion in non-insulin dependent
diabetes. N Engl J Med 19 88; 318 :12 31 12 39.
27. Polonsky KS, Sturis J, Bell BI. Non-insulin-dependent diabet...
Medical Management of Diabetes and Heart Disease - part 9 docx
... PTCA- and CABG-treated patients even in subgroups of
diabetes and three-vessel disease ( 31) . In addition to the randomized trials com-
paring PCI and CABG, three large, single-center registries and ... three-vessel disease, and this is
consistent with the 19 81 19 94 Emory experience where only 15 % of insulin-
dependent diabetics with three-vessel disease requiring r...
Medical Management of Diabetes and Heart Disease - part 10 potx
... diabetes, 11 0 11 3
Fibrinolytic agents,
CAD, 19 1 19 3
MI, 19 1 19 3
type 2 diabetes, 11 3 11 4
Fibrinolytic system, schematic, 54
Fibrinolytic Therapy Trialists’ Collabora-
tive Group, 19 1 19 2
Fibrinopeptide ... 12 6
metformin, 11 2
obesity, 14 9 15 0
OSA, 15 5 15 6
PAI -1 , 15 3 15 4
prevalence, 14 9
thrombosis, 15 3 15 4
treatment, 15 6 15 8
troglitazone, 11 2
Postexerci...